Ciclesonide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Ciclesonide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Report Description

Ciclesonide is an inhaled corticosteroids (ICS), recommended in asthma and chronic obstructive pulmonary disease (COPD) indication to get relief from difficulty in breathing, chest tightness, wheezing, and coughing. Inhaled drugs including inhaled corticosteroids, long acting β2 adrenoceptor agonists (LABA), and long acting muscarinic receptor antagonists (LAMA) are important treatment regime in the management of COPD. Inhaled corticosteroids are generally considered as safe and well tolerated in both adults and children. The improved safety and comparable efficacy profiles of ciclesonide demonstrated a potential treatment option which may lead to improved adherence and treatment outcome in asthma and COPD.

However, some of the studies raised concerns regarding increased risk of pneumonia related to regular use of ICS in adult patients with chronic obstructive pulmonary disease. A study findings published in the Respirology Journal: 2013, revealed an increased risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma regularly taking ICS. This could potentially lead to restrict application of ciclesonide by patients during the forecast period.

Market Dynamics
Factors such as high prevalence of allergy rhinitis and asthma, and frequent product approval and launches in key regions are expected to drive the market growth over the forecast period. For instance, according to the Global Asthma Report published in 2021, it was estimated that globally asthma kills around 1,000 people every day and affects as many as 339 million people, worldwide. Furthermore, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol indicated for treatment of allergic rhinitis and launched it in the U.S. market.
Moreover, increasing strategic mergers and acquisitions by key players is also expected to support and drive the market growth. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).
Key features of the study:
This report provides in-depth analysis of ciclesonide market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global ciclesonide market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study includes AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics.
The global ciclesonide market report caters to various stakeholders in this industry including investors, researchers, ciclesonide manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the ciclesonide market.
Detailed Segmentation:
Global Ciclesonide Market, By Indication:
Allergy Rhinitis
Asthma
Global Ciclesonide Market, By Dosage Form:
Aerosol
Nasal Spray
Global Ciclesonide Market, By Geography:
North America
By Country:
U.S.
Canada
By Indication:
Allergy Rhinitis
Asthma
By Dosage Form:
Aerosol
Nasal Spray
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Indication:
Allergy Rhinitis
Asthma
By Dosage Form:
Aerosol
Nasal Spray
Asia Pacific
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
By Indication:
Allergy Rhinitis
Asthma
By Dosage Form:
Aerosol
Nasal Spray
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Indication:
Allergy Rhinitis
Asthma
By Dosage Form:
Aerosol
Nasal Spray
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Indication:
Allergy Rhinitis
Asthma
By Dosage Form:
Aerosol
Nasal Spray
Africa
By Country:
North Africa
Central Africa
South Africa
By Indication:
Allergy Rhinitis
Asthma
By Dosage Form:
Aerosol
Nasal Spray
Company Profiles
AstraZeneca Plc*
Company Overview
Product Portfolio
Financial Performance
Recent Developments
Strategies
Cipla Limited
Sun Pharmaceutical Industries Ltd.
Apotex Inc.
“*” marked represents similar segmentation in other categories in the respective section.